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Available online 4 January 2016Background: Critical care patients are prone to venous thromboembolism (VTE) and, thus, pharmacological
thromboprophylaxis is generally advised. Low-molecular weight heparins (LMWHs) have become the drug of
choice in ICU patients, since their predictable and reproducible dose response. Monitoring their pharmacological
effect is not usually necessary except in special occasions (i.e. with obese or renal failure patients), where
anti-FXa level measuring is recommended. However, there is neither recommendation of adequate anti-FXa
levels in critically ill patients nor is it known whether peak or trough level should be measured. The aim of this
systematic review was to evaluate the recommended LMWH doses, and the reasons to monitor anti-FXa levels.
Methods:We searchedMEDLINE, Scopus, Cochrane Central Register of Controlled Trials and ClinicalTrials.com to
identify all potentially relevant studies. Prospective studies done in critically ill patients were included if at least
one anti-FXa level (i.e. peak or trough) after any speciﬁed LMWH thromboprophylaxis dose was measured.
Results: Total 18 eligible studies including 1644 patients were included. Therewas awide variation in themedian
peak anti-FXa levels (b0.1–0.35 IU/ml). Trough levels were generally low. Of note, none of the studies detected
any correlation with bleeding events and anti-FXa levels. Low trough level increased incidence of DVT in one
study only.
Conclusion: Based on the current literature, no deﬁnite conclusions can be drawn on targeted anti-FXa level in
critically ill patients when using LMWH thromboprophylaxis.






Critically ill patients are at increased risk of venous thromboembo-
lism (VTE) because of several additive risk factors [1,2], with the critical
illness itself acting as a hypercoagulable state [3,4]. In addition,
withholding anticoagulant prophylaxis because of an elevated bleeding
risk may predispose to VTE [5]. Therefore, the incidence of deep vein
thrombosis (DVT) varieswidely, from10% to almost 100% [2,6]. Hospital
mortality rates in patients with VTE have been reported to be relatively
high, up to 28% [7]. In addition, VTE has been associated with increased
risks of longer durations of mechanical ventilation and hospitalization
[1].
Current guidelines of the American College of Chest Physicians
(ACCP) recommend the use of low-molecular-weight heparin
(LMWH) or unfractionated heparin (UFH) to prevent VTE in critically
ill patients [8]. However, data supporting the thromboprophylactic
effects of LMWH and UFH are mainly based on studies in medical and
surgical ward patients, in which LMWHs were superior to UFH in
preventing VTE [9]. LMWHs have also become the drug of choice for pa-
tients in the intensive care unit (ICU) owing to their more predictable.and reproducible dose responses without the need for monitoring
[10]. Furthermore, LMWHshave a lower risk of heparin-induced throm-
bocytopenia than UFH [11]. However, despite the almost routine use of
pharmacological prophylaxis, the incidence of VTE has remained
relatively high, between 5% and 16% [11,12], raising questions about
the adequacy of current recommendations in heterogeneous high-risk
groups of ICU patients.
The antithrombotic effects of LMWHs are mainly owing to their en-
hancement of the inhibitory effects of the intrinsic anticoagulant anti-
thrombin III (AT III) on activated factor X (FXa) and thrombin (FIIa).
Each LMWHhas its own pharmacological proﬁle (i.e., molecular weight
distribution and anti-FXa/anti-FIIa activities),whichmust be considered
when interpreting laboratory results [13]. As all LMWHs are predomi-
nantly cleared by the kidneys, patients with renal insufﬁciency may be
predisposed to bleeding. Therefore, monitoring the pharmacological
effects of LMWHs bymeasuring anti-FXa levels has been recommended
only in patients with renal insufﬁciency or with other special circum-
stances (e.g., morbid obesity) [10]. To date, recommendations for ade-
quate anti-FXa levels in critically ill patients have not been proposed,
nor is it known whether the peak or trough level should be measured.
Peak levels are generally regarded as reﬂecting thromboprophylactic ef-
fect, whereas trough levels are regarded as reﬂecting accumulation.
However, it is unclear whether high peak levels predispose to bleeding
11A. Vahtera et al. / Thrombosis Research 139 (2016) 10–16or low trough levels to thrombosis. This systematic review was
designed to determine anti-FXa levels in blood of critically ill patients
after prescribed LMWH thromboprophylaxis and to evaluate whether
clinically relevant events (e.g., VTE or bleeding) correlate with anti-
FXa levels.
2. Methods
This systematic review is based on themethodology recommendedby
the Cochrane Collaboration. PRISMA Statement andMoose reporting rec-
ommendations were used. The protocol was published on the PROSPERO
register (www.crd.york.ac.uk/PROSPERO, number CRD42015025744)
before ﬁnal data extraction.
2.1. Data sources and search strategy
MEDLINE, SCOPUS, the Cochrane Library, and the ClinicalTrials.com
databaseswere searched in collaborationwith a librarian from theUniver-
sity of Helsinki, using the termsVenous Thrombosis/thromboprophylaxis/
Venous ThromboembolismANDCritical Care/Intensive CareUnit/Critical
Illness AND LMWH. Therewere no restrictions on language, date, or type
of publication. The initial search was completed in May 2015. The refer-
ence lists of all retrieved articles weremanually reviewed to identify any
potentially relevant studies. Details of the search strategies are shown in
Supplemen 1.
2.2. Study selection
Predeﬁned inclusion criteria were used. Studies had to be prospec-
tive in design, performed in adult (age N18 years) critical care patients,
include more than 10 patients, use any LMWH thromboprophylaxis,
and include at least one anti-FXa measurement at a known time point
after speciﬁed LMWH administration. All abstracts and titles were
screened independently by two reviewers (AV and AK). The full text
of every identiﬁed article was read. Agreement between the two
reviewers on article inclusion was high (kappa value 0.89), with any
disagreements resolved through discussions.Fig. 1. Flow chart of th2.3. Data extraction and quality assessment
The selected studies were independently reviewed by the same two
investigators (AV and AK), and data were extracted using predeﬁned
criteria, including the study design, patient population, anti-FXa results,
and clinical outcomes (i.e., DVT, symptomatic DVT, pulmonary embo-
lism (PE), symptomatic PE, and major or minor bleeding based on the
original trial deﬁnition). The quality of eligible studies was assessed
using theDowns and Black checklist [14], and any disagreementwas re-
solved by consensus. Quality assessment is presented as total Downs
and Black score (maximum, total score 27), as well as by subgroup
scores (reporting, external validity, internal validity-bias, internal
validity-confounding). Because of the high heterogeneity of clinical
outcomes in included studies, quantitative analyses could not be
performed.
3. Results
The initial search identiﬁed 5206 citations, after duplicates were re-
moved. Of these, 31 studieswere retrieved for more detailed evaluation
and 18 studies, including 1644 patients, were included in the ﬁnal
systematic review (Fig. 1). These studies were mainly observational,
with only two randomized clinical trials (RCTs) identiﬁed. Trial charac-
teristics are presented in Table 1. Most of these studies (10 observation-
al studies and two RCTs) tested the effects of different dosages of
enoxaparin [15–26], whereas four observational studies assessed
dalteparin [27–30], and one each tested certoparin [31] and nadroparin
[32]. No studies testing tinzaparin were identiﬁed. The median peak
anti-FXa levels in ICU patients varied widely, from b0.1 IU/mL [31] to
0.35 IU/mL [27]. The median trough anti-FXa levels were reported in
four studies, and they varied between undetectable and b0.1 IU/mL
[27,31,18,20].
The quality of the studies according to the Down and Black score is
shown in Table 2. The median total score (interquartile range, IQR)
was 19 [15–20]/27. The median subscores (IQR) were 8.5 [7–10]/11
for reporting, 1 [1–2]/3 for external validity, 5 [4–5]/7 for internal
validity-bias, and3 [2–5]/7 for internal validity-confounding andpower.e study selection.
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The only observational study of certoparin included 62 critically ill
patients. Treatment with 3000 IU OD certoparin resulted in a median
peak anti-FXa level that was undetectable b0.1 (IQR b0.1–0.2) IU/mL.
Only 28% of patients were within the antithrombotic range using the
study deﬁnition of target value. When the dosage was doubled to
3000 IU bid, the median peak anti-FXa level did not change but 47% pa-
tients were within the recommended range. Median trough levels in
patients administered 3000 IUODand bid certoparinwere undetectable
b0.1 (IQR b0.1–0.17) and b0.1 (IQR b0.1–0.26) IU/mL, respectively. One
patient in the lower dose group experienced severe PE, but the anti-FXa
concentration of this patientwas not reported. Therewas no correlation
between bleeding and high anti-FXa levels (N0.3 IU/mL) [31].3.2. Dalteparin
Four studieswere identiﬁed. The ﬁrst study, involving patients in the
ICU with renal insufﬁciency (creatinine clearance “CrCl” b 30 mL/min)
administered 5000 IU OD dalteparin, reported median peak anti-FXa
levels 4 h (hrs) after treatment to be 0.29 (IQR 0.20–0.42) IU/mL after
3 days and 0.34 (IQR 0.27–0.45) IU/mL after 17 days. Trough levels
were undetectable. The incidence of major bleeding was 7.2% and two
patients died of bleeding complications. However, there was no correla-
tion between anti-FXa levels and deaths [27]. Similar results were ob-
served in a small observational study of patients with renal
insufﬁciency (CrCl b 30 mL/min) [29].
The third study was a before and after study, in which dalteparin
dosage was doubled if the anti-FXa level at 12 h was below b0.1 IU/
mL. The protocol reduced the total incidence of VTE (12.8% vs. 7.0%,
p = 0.009). Moreover, if the median anti-FXa level was below
b0.1 IU/mL at 12 h, the rates of VTE (14.4% vs. 5.4%, p = 0.05) and
DVT (14.4%. vs. 3.2% p = 0.01) were signiﬁcantly higher [28].
In the fourth study, the pharmacokinetics of dalteparin were
assessed in edematous and non-edematous ICU patients. There were
no between-group differences in mean ± standard deviation (SD)
peak (0.15 ± 0.05 vs. 0.14 ± 0.06 IU/mL) and trough (0.05 ± 0.06 vs.
0.02 ± 0.02 IU/mL) anti-FXa concentrations [30].3.3. Enoxaparin
Median peak anti-FXa levels tended to be lower in ICU than in med-
ical ward patients: 0.16 (IQR 0–0.22) vs 0.2 (IQR 0.15–0.27) IU/mL [16].
Similar results were observed when the area under curve (AUC)0–12 h
was measured (SD 2.63 ± 1 vs. 4.26 ± 1.7 IU/mL/h) [21]. Two RCTs
also showed positive correlations between enoxaparin dosage and me-
dian peak and mean anti-FXa levels [22,23]. Five studies reported
trough levels, which were generally low (0–0.10 IU/mL) and in one
study the low trough level correlated with the incidence of DVT (37
vs. 11%, p=0.026) [19].Median trough levelswere generally lowor un-
detectable [18,20]. Nine studies reported adverse events, with none of
these studies detecting any correlation between bleeding events and
anti-FXa levels [15,18–20,22,23,24,33,26].3.4. Nadroparin
Only one observational study was found, in which nadroparin
2850 IU OD was compared in three different patient groups: ICU pa-
tients on vasopressors (n = 15), ICU patients not on vasopressors
(n = 15), and surgical ward patients (n = 15). The mean peak anti-
FXa levels at 3 h were 0.09 (95% conﬁdence interval (CI) 0.05–0.10),
0.23 (95% CI 0.18–0.27), and 0.28 (95%CI 0.23–0.31) IU/mL respectively.
Trough levels were not measured, and clinical outcomes were not re-
ported [32].4. Discussion
This systematic review,which included 16 observational studies and
two RCTs, found a lack of evidence regarding optimal targeted anti-FXa
levels in critically ill patients. Median peak anti-FXa levels
(b0.1–0.35 IU/mL) [31,27] and mean anti-FXa levels (0.09–0.40 IU/
mL) [32,23] varied widely, depending on the type and dose of LMWH
and on the study population. In addition, the trough levels were consis-
tently low [27,31,18,20,29,30,24,33]. Data on peak and trough anti-FXa
levels after LMWH thromboprophylaxis in ICU patients are sparse, and
more research is certainly needed. Irrespective of LMWH drug and
dose, peak and trough anti-FXa levels were generally low throughout
the studies, but correlations between anti-FXa levels and clinically rele-
vant outcomes, such as DVT, PE, and bleeding, remain uncertain. How-
ever, one study found that a low trough anti-FXa level signiﬁcantly
increased the incidence of DVT (37% vs. 11%, p = 0.026) [19].
These ﬁndings may have several explanations. First, AT III levels in
critically ill patients were consistently low, correlating with low anti-
FXa levels [31,21]. Low AT III levels may be due to elevated levels of
other heparin-binding proteins (e.g., ﬁbronectin and vitronectin), as ob-
served in an animal endotoxin model [34]. Second, the absorption of
subcutaneously administered LMWHmay be reduced in patients treat-
edwith a vasopressor, reducing systemic bioavailability [32]. Third, crit-
ically ill patients often receive excessive amounts of intravenous ﬂuids,
resulting in peripheral edema,whichmay affect LMWHpharmacokinet-
ics and reduce its bioavailability [17].
Administration of a standard prophylactic dosage of LMWH to obese
ICU patients results in lower anti-FXa activity than in non-obese indi-
viduals [28,20]. However, enoxaparin dose may be positively correlated
with anti-FXa levels, with adequate peak anti-FXa levels achieved using
a weight-adjusted dose of enoxaparin (1 mg/kg once daily) [23].
Because of the lack of good quality RCTs [35], evidence of the effec-
tiveness of LMWH thromboprophylaxis in ICU patients is mainly
based on measurements of plasma levels of anti-FXa, as anti-FXa is a
surrogate marker for anticoagulant effects. Correct anti-FXa levels
have been determined only in patients undergoing orthopedic surgery
[36,9]. It has not yet been determined whether peak or trough level
should be measured. The generally recommended peak anti-FXa level
for thromboprophylaxis is 0.1–0.3 IU/mL in medical and surgical pa-
tients [37]. The rates of VTE in patients undergoing hip surgery with
trough (12 h after administration of enoxaparin) anti-FXa activity of
N0.1 IU/mL, b0.1 IU/mL, and b0.05 IU/mL were reported to be 6.3%,
14.6%, and 18.8%, respectively. Anti-FXa levels N0.2 IU/mL were associ-
ated with hematomas [36]. These values are also generally used as ref-
erences for anticoagulant effects in ICU patients in the observational
studies included in this review.
Two of the observational studies were conducted in critically ill pa-
tients with renal insufﬁciency. Administration of a prophylactic dose
of dalteparin to patients with impaired renal function (CrCl b 30 mL/
min) did not altermedian peak anti-FXa levels [29,27] norwas there ev-
idence of an increased risk of bleeding, despite a mean ± SD CrCl of
18.9 ± 6.5 mL/min [27]. Lower serum creatinine and urea levels (not
speciﬁed) were associated with a greater clearance of LMWH
(certoparin), as measured by lower plasma anti-FXa levels [31].
Renal insufﬁciency is one of the most frequent reasons for omission
of pharmacological thromboprophylaxis or for preferring UFH over
LMWH [5]. Current research evidence does not support this practice,
but these data are observational and limited. Moreover, urinary CrCl is
an imprecise estimate of glomerular ﬁltration rate in critically ill pa-
tients [38]. A meta-analysis that included patients with severe renal in-
sufﬁciency (CrCl b 30mL/min) found that only when therapeutic doses
of enoxaparin were administered were anti-FXa levels elevated and the
risk of major bleeding increased [39]. Prophylactic administration of
enoxaparin but not of tinzaparin showed similar accumulation ﬁndings
in elderly medical patients with impaired renal function (CrCl 34 ±
11.4 mL/min) [40].
Table 1
The characteristics of the selected studies.







Adverse events Anti-FXa assay
Certoparin
[31] Mixed ICU Single-center, prospective,
open label study (n = 30 +
32)
Certoparin 3000 IU s.c. OD and
3000 IU s.c. bid
At 0, 4, 12 and 24 h Median (IQR) at 4 h b














label study (n = 138/156)
Dalteparin 5000 IU s.c. OD At 0, 1, 2, 4, 8, 12, 20
and 24 h and on
days 3, 10 and 17
Median (IQR) at 4 h:





(b0.10– b 0.10) (n =
120)
5.1% DVT, 7.2% major bleeding,





[28] TICU Single-center, before and after,
prospective study (n =
190/785)
Before: dalteparin 5000 IU s.c
OD, after: dalteparin 5000 IU
s.c. OD if anti-Xa b0.1 IU/ml
5000 IU s.c. bid
At 12 h Not measured Not measured Pre vs. post protocol: overall







cohort study (n = 19)
Dalteparin 5000 IU s.c. OD At 4 h and 22–23 h Mean (95% CI) at 4 h
0.30 (0.27–0.33)







[30] Mixed ICU Two-center open label study,
edematous (n = 7) vs.
nonoedematous (n = 7)
Dalteparin 2500 IU s.c. OD At 0, 3, 4, 6, 8, 12
and 24 h
Mean (SD) at 3 h: 0.15
(0.05) vs. 0.14 (0.06)
Mean (SD) 0.05 (0.06)
vs. 0.02 (0.02)
Not reported Spectrolyze Heparin Xa©
Enoxaparin
[15] SICU (trauma ISS
24 ± 10.9)
Single-center, prospective, open
label study (n = 61). LMWH
dosing was increased if peak
anti-FXa was b0.2 IU/ml
Enoxaparin 30 mg s.c. bid
(initial dose) up to 60 mg s.c.
bid
At 4 h on the 3rd
dose and before the
4th dose
At 4 h sub-therapeutic
(b0.2) in 70.5% (n =
43)
Not reported 4.9% VTE, did not correlate to
anti-FXa levels. No bleeding
events.
HemosilIL©



















Adverse events Anti-FXa assay
[16] MICU vs. general
medical ward
Single-center, prospective,
controlled open label study
(n = 15 + 16)
Enoxaparin 40 mg s.c. OD at 0, 1, 3, 6 and 12 h Median (IQR) 3 h 0.16
(0–0.22) vs. 0.2
(0.15–0.27)
Not measured Not reported Rotachrom HBPM/LMWH©
[17] TICU (ISS N10) Single-center, prospective
cohort study, nonoedematous (n
= 11/14) vs. edematous (n =
10/11).
Enoxaparin 30 mg s.c. bid At 0, 5, 1, 2, 3, 4, 6, 8
and 12 h
Median 0.27 vs. 0.12.
IQR not reported
Not reported Not reported Chorm Z Heparin Kit©
[18] MICU Single-center, prospective,
observational study (n = 55)




12.7% DVT, 1.8% PE. No
bleeding complications
STA-STACLOT Heparin©
[19] SICU Single-center, prospective,
observational study (n = 54)
Enoxaparin 30 mg s.c. bid At 4 h and 1 h before
the 4th dose
Mean (SD) at 4 h low
trough group 0.17 (0.1)
vs. normal trough group
0.27 (0.1)
Low trough (≤0.1) n =
27 vs. normal trough
(N0.1) n = 27
Low through anti-FXa level
correlated to incidence of DVT
(37 vs. 11%, p = 0.026)
Not reported
[20] Mixed ICU Single-center, prospective,
observational study (n = 89)











controlled open label study
(n = 16 + 13)
Enoxaparin 40 mg s.c. OD At 0, 1, 3, 6, 12 h on
day 1 and at 3 h on
days 2–5
Mean AUC (SD) at 0–12
h 2.63 (1) vs. 4.26 (1.7)
Not measured Not reported Rotachrom HBPM/LMWH©
[22] Mixed ICU Single-center, prospective,
randomized double blind study
(n = 18 + 16 + 20 + 18)
Enoxaparin 40, 50, 60 or 70 mg
s.c. OD
At 0, 4, 12 and 24 h Median at 4 h 0.13,
0.14, 0.27 vs. 0.29. IQR
not reported
Not reported One minor nosebleed Coamatic Heparin©
[23] Mixed ICU Single-center, prospective,
randomized double blind study
(n = 20 + 20 + 19 + 19)
Enoxaparin 40 mg s.c. OD, 30
mg s.c. bid, 40 mg s.c. bid or 1
mg/kg s.c. OD
At 0, 4, 12, 16, 24 h
daily for 3 days
Mean at 4 h on the 1st
day: 0.20, 0.08, 0.17,
0.34 on the 3rd day:
0.13, 0.14, 0.33, 0.40. SD
not reported
Not reported No adverse events Coamatic Heparin©
[24] TICU (ISS N10) Single-center, prospective, open
label, cohort study (n = 17)
Enoxaparin 40 mg s.c. OD At 4 and 24 h (on day
3)
Mean (SD) at 4 h 0.19
(0.09)
Mean (SD) 0.04 (0.04) One DVT, no bleeding Not reported
[33] Mixed ICU Single-center, prospective, open
label study (n = 36)




One DVT, one bleeding, one
thrombocytopenia




open label study (n = 16)
Enoxaparin 40 mg s.c. OD At 4 h on days 1, 2,
3, 6, 9, 12 and 15
Mean (SD) at 4 h 0.17
(0.17)
Not measured One DVT, two bleeding events Coamatic Heparin©
Nadroparin
[32] ICU vs. general
surgery ward
Single-center, ICU patients on
vasopressors (n = 15) vs. ICU
patients not on vasopressors
(n = 15) vs. surgical ward
patients (n = 15)
Nadroparin 2850 IU s.c. OD At 0, 3, 4, 6, 8 and 12
h, LMWH given at
least 3 days




Not measured Not reported Coamatic Heparin©
Abbreviations
ICU, indicates intensive care unit; CrCl, creatinine clearance; TICU, trauma intensive care unit; SICU, surgical intensive care unit; MICU, medical intensive care unit; ISS, injury severity score; LMWH, low-molecular weight heparin; s.c., subcutaneous;




























[15] 8 6 1 0 1
[32] 15 8 1 4 2
[27] 20 10 1 6 3
[28] 13 7 2 4 0
[16] 19 9 1 5 4
[17] 15 6 1 5 3
[31] 19 8 1 5 5
[18] 22 10 3 5 4
[19] 17 7 3 4 3
[20] 20 9 1 5 5
[21] 16 7 1 5 3
[29] 14 8 0 4 2
[23] 26 10 2 7 7
[22] 23 9 1 7 6
[30] 21 10 1 5 5
[24] 14 8 0 4 2
[33] 20 11 1 5 3
[26] 20 10 1 5 4
Median (IQR) 19 (15–20) 8.5 (7–10) 1 (1–2) 5 (4–5] 3 [2–5)
IQR indicates interquartile range.
Reporting
1. Is the hypothesis/aim/objective of the study clearly described?
2. Are the main outcomes to be measured clearly described in Sections 1 and 2?
3. Are the characteristics of the patients included in the study clearly described?
4. Are the interventions of interest clearly described?
5. Are the distributions of principal confounders in each group of subjects to be com-
pared clearly described?
6. Are the main ﬁndings of the study clearly described?
7. Does the study provide estimates of the random variability in the data for the main
outcomes?
8. Have all important adverse events that may be a consequence of the intervention
been reported?
9. Have the characteristics of patients lost to follow-up been described?
10. Have actual probability values been reported (e.g. 0.035 rather than b0.05) for the
main outcomes except where the probability value is less than 0.001?
External validity
1. Were the subjects asked to participate in the study representative of the entire popula-
tion from which they were recruited?
2. Were those subjects who were prepared to participate representative of the entire
population from which they were recruited?
3. Were the staff, places, and facilities where the patients were treated, representative of
the treatment the majority of patients receive?
Internal validity — bias
1. Was an attempt made to blind study subjects to the intervention they have received?
2. Was an attempt made to blind those measuring the main outcomes of the intervention?
3. If any of the results of the study were based on “data dredging”, was this made clear?
4. In trials and cohort studies, do the analyses adjust for different lengths of follow-up of
patients, or in case–control studies, is the time period between the intervention and
outcome the same for cases and controls?
5. Were the statistical tests used to assess the main outcomes appropriate?
6. Was compliance with the intervention/s reliable?
7. Were the main outcome measures used accurate (valid and reliable)?
Internal validity — confounding (selection bias) and power.
1. Were the patients in different intervention groups (trials and cohort studies) or were
the cases and controls (case–control studies) recruited from the same population?
2. Were study subjects in different intervention groups (trials and cohort studies) orwere
the cases and controls (case–control studies) recruited over the same period of time?
3. Were study subjects randomized to intervention groups?
4. Was the randomized intervention assignment concealed fromboth patients and health
care staff until recruitment was complete and irrevocable?
5. Was there adequate adjustment for confounding in the analyses from which the main
ﬁndings were drawn?
6. Were losses of patients to follow-up taken into account?
7. Did the study have sufﬁcient power to detect a clinically important effect where the
probability value for a difference being due to chance is less than 5%?
15A. Vahtera et al. / Thrombosis Research 139 (2016) 10–16The critical illness itself often acts as a hypercoagulable state
(e.g., sepsis or trauma) [3]. In addition, the severity of critical illness
(e.g., multiple organ dysfunction score or severity of burn injury) was
reported to correlate with lower anti-FXa [41,20]. Whether the latterreﬂects an insufﬁcient anticoagulant effect or the nature of anti-FXa as
a surrogate marker requires further investigations.
Theseﬁndings of low levels of anti-FX activity and several conditions
that can alter LMWH bioavailability in intensive care patients have
raised the question of the adequacy of thromboprophylaxis with dosing
schemas applied to medical and surgical patients. Although VTE events
have decreased with LMWH prophylaxis, thromboembolism has
occurred, despite recommended dosing of LMWHs and even within
recommended anti-FXa levels [19]. In addition to the reasons described
above, uneventful thrombosis may result from a fear of bleeding,
resulting in pauses and delays in thromboprophylaxis [5].
4.1. Strengths and limitations
To our knowledge, this is the ﬁrst systematic review of the role of
anti-FXa monitoring during LMWH thromboprophylaxis in critically ill
patients. However, this study had several limitations. First, all included
studies were relatively small, withmost being observational and under-
powered for clinical endpoints, and of lowquality. Second, as the type of
ICUs varied among studies (i.e., mixed, medical, trauma, and surgical)
and patients had various degrees of renal failure, the study population
was quite heterogeneous. The beneﬁts and adverse effects of LMWH
may vary in different subgroups of ICU patients. Third, the type and
dose of LMWH varied among studies; because LMWHs have different
pharmacological properties, it is unclear whether anti-FXa levels can
be generalized. Fourth, there were methodological limitations
concerning anti-FXa measurements, as the protocols of the included
studies were not identical (e.g., times samples were obtained after
LMWH administration, blood sample collecting procedures, and delay
from sampling to analysis) and the analytic methods and reference
levels differ among laboratories. Moreover, the reporting of measured
anti-Xa activity concentrations in the studies varied (e.g., median,
mean or AUC), making data interpretation difﬁcult. Fifth, the secondary
outcomes should also be considered a study limitation because the
deﬁnitions of these adverse events (e.g., DVT, symptomatic DVT, PE,
symptomatic PE, and minor or major bleeding) varied across studies.
Sixth, the literature searchwas updated inMay 2015; thus, more recent
data may be missing.
5. Conclusion
No deﬁnite conclusions can be drawn regarding target anti-FXa levels
in critically ill patients administered LMWHs for thromboprophylaxis. No
recommendations can be made on the timing of anti-FXa monitoring or
for dose adjustments for individual patients.
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